Fc gamma R2B B2.4 haplotype predicts increased risk of red blood cell alloimmunization in sickle cell disease patients

Imagem de Miniatura
Arquivos
art_COSTA NETO_Fc_gamma_R2B_B24_haplotype_predicts_increased_risk_2020.PDF.pdf (231.81 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
SANTOS, Flavia
KASHIMA, Simone
COVAS, Dimas
MOREIRA, Frederico
Citação
TRANSFUSION, v.60, n.7, p.1573-1578, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND Red blood cell (RBC) alloimmunization is an important transfusion complication which is prevalent among sickle cell disease (SCD) patients. Autoimmune diseases are a known risk factor for RBC alloimmunization, suggesting that autoimmunity and post-transfusion alloantibody development occur through similar physiopathological pathways. Polymorphisms in the Fc gamma R2B gene have already been associated with several autoimmune disorders and hypothetically could be associated with RBC alloimmunization. Our goal was to evaluate if important polymorphisms of Fc gamma R2B have an impact on the risk of RBC alloimmunization among SCD patients. STUDY DESIGN AND METHODS This was a case-control study in which alloimmunized and non-alloimmunized SCD patients were compared in terms of the genotype frequency of the Fc gamma R2B polymorphisms -386G/C, -120 T/A, and 695C/T, genotyped through direct Sanger sequencing. RESULTS A total of 237 patients met the eligibility criteria, 120 cases (alloimmunized) and 117 controls (non-alloimmunized). RBC alloimmunization was associated with female sex (p < 0.001), lifetime number of RBC units transfused (p = 0.002) and 120 T/A Fc gamma R2B genotype (p = 0.031). The Fc gamma R2B promoter region haplotype 2B.4 (386C120A) was positively associated with RBC alloimunization (p = 0.045). The logistic regression (LR) model identified female sex (OR 10.03, CI 95% 5.16-19.49; p < 0.001) and Fc gamma R2B 2B.4 haplotype (OR 4.55, CI95% 1.1118.65; p = 0.035) as independent predictors of RBC alloimmunization in SCD patients. CONCLUSION SCD patients with the Fc gamma R2B 2B.4 haplotype had over a fourfold higher risk for RBC alloimmunization. This highlights the role played by Fc gamma R2B on RBC alloimmunization and may be helpful in identifying the immune responders.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/36758
Referências
  1. Carneiro-Proietti ABF, 2018, BRIT J HAEMATOL, V182, P895, DOI 10.1111/bjh.15462
  2. Chou ST, 2013, BLOOD, V122, P1062, DOI 10.1182/blood-2013-03-490623
  3. Chu ZT, 2004, TISSUE ANTIGENS, V63, P21, DOI 10.1111/j.1399-0039.2004.00142.x
  4. Dezan M. R., 2016, ISBT SCI SERIES, V11, P132
  5. Dinardo Carla Luana, 2013, Rev. Bras. Hematol. Hemoter., V35, P414, DOI 10.5581/1516-8484.20130123
  6. Espeli M, 2016, IMMUNOL REV, V269, P194, DOI 10.1111/imr.12368
  7. Fasano RM, 2015, BRIT J HAEMATOL, V168, P291, DOI 10.1111/bjh.13123
  8. Hanchard NA, 2014, TRANSFUS MED HEMOTH, V41, P453, DOI 10.1159/000369079
  9. Hargreaves CE, 2015, IMMUNOL REV, V268, P6, DOI 10.1111/imr.12341
  10. Hendrickson JE, 2006, TRANSFUSION, V46, P1526, DOI 10.1111/j.1537-2995.2006.00946.x
  11. Hendrickson JE, 2016, HEMATOL-AM SOC HEMAT, P446, DOI 10.1182/asheducation-2016.1.446
  12. Higgins JM, 2008, BLOOD, V112, P2546, DOI 10.1182/blood-2008-03-146415
  13. Lassauniere R, 2016, GENES IMMUN, V17, P93, DOI 10.1038/gene.2015.60
  14. Mackay M, 2006, J EXP MED, V203, P2157, DOI 10.1084/jem.20051503
  15. Meinderts SM, 2017, BLOOD, V130, P2121, DOI 10.1182/blood-2017-05-784876
  16. Miller ST, 2013, TRANSFUSION, V53, P704, DOI 10.1111/j.1537-2995.2012.03796.x
  17. Milton JN, 2014, BLOOD, V124, P762
  18. Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
  19. Papay P, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.11.028
  20. Radstake TRDJ, 2006, ARTHRITIS RHEUM-US, V54, P3828, DOI 10.1002/art.22275
  21. Ryder AB, 2016, BRIT J HAEMATOL, V174, P483, DOI 10.1111/bjh.13781
  22. Satoh T, 2013, BLOOD, V122, P1991, DOI 10.1182/blood-2013-05-501858
  23. Silvy M, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.104703
  24. Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x
  25. Su KH, 2004, J IMMUNOL, V172, P7186, DOI 10.4049/jimmunol.172.11.7186
  26. Verduin EP, 2016, TRANSFUSION, V56, P1849, DOI 10.1111/trf.13648
  27. VICHINSKY EP, 1990, NEW ENGL J MED, V322, P1617, DOI 10.1056/NEJM199006073222301
  28. Vichinsky EP, 2001, SEMIN HEMATOL, V38, P14, DOI 10.1053/shem.2001.20140
  29. Yazdanbakhsh K, 2016, HEMATOL-AM SOC HEMAT, P457, DOI 10.1182/asheducation-2016.1.457
  30. Yazdanbakhsh K, 2012, BLOOD, V120, P528, DOI 10.1182/blood-2011-11-327361

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - IMT
Carregar mais